BMY vs PFE: Bristol-Myers Squibb and Pfizer compared
The short version
From the latest prices and each company's SEC filings. Who's ahead on each measure, not which to buy.
- Pfizer is the larger company, worth $159.3B, about 1.3 times Bristol-Myers Squibb.
- Bristol-Myers Squibb grew revenue faster over the last year (+5.7% vs +2.6%).
- On earnings, Bristol-Myers Squibb is the cheaper stock (16.7x vs 21.3x).
- Pfizer's price assumes faster free cash flow growth: about 3% a year, against -5% for Bristol-Myers Squibb (reverse DCF).
Side by side
The stronger figure is shaded where higher (or, for valuation multiples, lower) reads as better. How the implied growth works.
| Measure | BMY | PFE |
|---|---|---|
| Market cap | $122.0B | $159.3B |
| Share price | $59.12 | $28.28 |
| Revenue (last fiscal year) | $48.2B | $62.6B |
| Free cash flow (last fiscal year) | $12.8B | $9.1B |
| Revenue growth, last year | +5.7% | +2.6% |
| Revenue growth per year, last 5 fiscal years | +1.0% | -4.0% |
| Operating margin | 24.2% | — |
| Net margin | 18.9% | 6.8% |
| Return on equity | 41.6% | 5.1% |
| P/E (trailing) | 16.7x | 21.3x |
| Price / free cash flow | 9.50x | 17.5x |
| EV / EBITDA | 9.29x | 15.4x |
| FCF growth the price implies | -4.9% | 3.3% |
| Dividend yield | 4.2% | 6.2% |
| Debt / equity | 2.93x | 1.36x |
| Fundamental grade | B | C |
| Superinvestors holding it | 13 | 14 |
| Insider purchases, last 12 months | 10 | 4 |
Results from SEC filings
Revenue and free cash flow by fiscal year, from each company's 10-K filings.
Bristol-Myers Squibb
| Year | Revenue | Free cash flow | Op. margin |
|---|---|---|---|
| 2021 | $46.4B | $15.2B | 17.5% |
| 2022 | $46.2B | $11.9B | 16.7% |
| 2023 | $45.0B | $12.7B | 18.8% |
| 2024 | $48.3B | $13.9B | -17.3% |
| 2025 | $48.2B | $12.8B | 19.4% |
Pfizer
| Year | Revenue | Free cash flow | Op. margin |
|---|---|---|---|
| 2021 | $73.6B | $29.9B | — |
| 2022 | $91.8B | $26.0B | — |
| 2023 | $50.9B | $4.8B | — |
| 2024 | $63.6B | $9.8B | — |
| 2025 | $62.6B | $9.1B | — |
Where the revenue comes from
Bristol-Myers Squibb · by products, 2025
Eliquis$14.4B30%
Opdivo$10.0B21%
Orencia$3.7B8%
Revlimid$3.0B6%
Yervoy$2.9B6%
Pomalyst/Imnovid$2.7B6%
Pfizer · by segments, 2023
Biopharma$57.2B98%
Business Innovation Segment$1.3B2%
Compare them in fullFifteen years of statements, quarterly results, DCF and IRR models, and any number of peers side by side.
Open BMY in InvestinglyQuestions
Which is bigger, Bristol-Myers Squibb or Pfizer?
Pfizer (PFE), at $159.3B against $122.0B.
Is BMY or PFE cheaper?
By trailing P/E, Bristol-Myers Squibb (16.7x) is cheaper than Pfizer (21.3x). A lower multiple can also mean the market expects less growth.
Which grows faster, BMY or PFE?
Bristol-Myers Squibb: revenue grew +5.7% over the last year, against +2.6%.
More comparisons
Prices and ratios as of the last daily update; statements from SEC filings. Information only, not investment advice.